FOSAMAX Once Weekly 70 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

fosamax once weekly 70 mg tablets

merck sharp & dohme ireland (human health) limited - alendronate sodium - tablet - 70 milligram(s) - bisphosphonates; alendronic acid - bisphosphonate, for the treatment of bone diseases - it is indicated in adults for the treatment of postmenopausal osteoporosis. fosamax reduces the risk of vertebral and hip fractures.

ISENTRESS 400 MG TABLETS Israel - English - Ministry of Health

isentress 400 mg tablets

merck sharp & dohme (israel - 1996) company ltd, israel - raltegravir as potassium - film coated tablets - raltegravir as potassium 400 mg - raltegravir - isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adult patients.this indication is based on safety and efficacy data from two double-blind, placebo-controlled trials in treatment-experienced patients and one double-blind, active-controlled trial in treatment-naive patients.

EMEND 125 MG CAPSULES Israel - English - Ministry of Health

emend 125 mg capsules

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

JANUET XR 1001000 MG TABLETS Israel - English - Ministry of Health

januet xr 1001000 mg tablets

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 100 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

JANUET 50 MG1000 MG Israel - English - Ministry of Health

januet 50 mg1000 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 1000 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUET 50 MG500 MG Israel - English - Ministry of Health

januet 50 mg500 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUET 50 MG850 MG Israel - English - Ministry of Health

januet 50 mg850 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUET XR 501000 MG TABLETS Israel - English - Ministry of Health

januet xr 501000 mg tablets

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

JANUET XR 50500 MG TABLETS Israel - English - Ministry of Health

januet xr 50500 mg tablets

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 500 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

JANUVIA 100 MG Israel - English - Ministry of Health

januvia 100 mg

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - film coated tablets - sitagliptin as monohydrate phosphate 100 mg - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.